knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 07:22:13 - browse：33473

Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her sons’ type 1 diabetes, never for herself. Her OB-GYN had put her on Effexor for her depression 20 years ago, and it worked well enough — she could sleep for the first time in her life, and she no longer cried at every little thing. But it never worked for her dark thoughts.

But then she retired, and then she had time, and then she saw an email — “I guess once your name gets on a list, it’s there,” she said — for an experimental depression drug called zuranolone.

Unlike today’s crowded market of SSRIs, prescribed once and taken for months, years, or even indefinitely, zuranolone, developed by Sage Therapeutics, promises something different.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Testing GLP

WSS

Newly revealed memo details efforts to keep Trump in power following election loss

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

Biotech investment managers search for lucrative opportunities

Kim Kardashian sparks debate on benefits of full

Readout Newsletter: Illumina, CRISPR, Regeneron

Target recalls 2.2 million additional candles due to laceration, burn hazards

knowledge

knowledge

leisure time

Malaria cases in Florida and Texas: Here’s what you need to know

Maui funeral service workers on devastation of fires: 'I'm in shock'

Novavax promises a turnaround & Lilly roils the obesity market

Faced with fears of OxyContin misuse, sales reps touted its safety

Heart attack and stroke risk calculators need revising

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The perfect storm of weather conditions that led to the devastating wildfires in Maui

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

GOP presidential candidates start declaring their loyalty

focus

Mirador, a new biotech startup, launches with $400 million

Readout LOUD podcast, live from the STAT Breakthrough Summit East

An innovative path out of biotech’s “valley of death”

Some of the ways extreme heat will change life as we know it

Medical devices makers are asking for forgiveness, not permission

Diabetes management: Digital health tools fall short, study says

entertainment

hotspot

focus

knowledge